공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

간염 치료제 시장 : 성장, 동향, 예측(2020-2025년)

Hepatitis Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 05월 상품 코드 940583
페이지 정보 영문
가격
US $ 4,250 ₩ 5,044,000 PDF (Single User License)
US $ 4,750 ₩ 5,637,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 7,121,000 PDF (Site License)
US $ 7,500 ₩ 8,901,000 PDF (Corporate License)


간염 치료제 시장 : 성장, 동향, 예측(2020-2025년) Hepatitis Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 05월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

간염 치료제 시장은 예측 기간 중 3.5%의 CAGR이 될 것으로 예상됩니다. 간염은 간의 염증 또는 붓기입니다. 간염은 약물, 알코올 사용, 또는 특정 병상이 원인으로 발생할 수 있습니다. 그러나 대부분의 경우는 바이러스성 간염으로 불리는 바이러스가 원인이 되며, A형, B형, C형 등 3개 유형의 간염이 대표적입니다. 간염은 매우 일반적인 질환이며, 간의 심각한 반흔화(간경변)로 연결되어 치명적인 간부전이 될 가능성이 있습니다./p>

간염의 일반적인 증상으로는 식욕 부진, 구역·구토, 피로, 발열, 몸의 통증, 위통 등이 있습니다. 사람에 따라 옅은 색의 변통, 진한 색의 소변, 피부 및 눈의 황변(황달) 등의 증상이 나타나기도 합니다. 간의 바이러스 감염증은 A형 간염, B형 간염, C형 간염, D형 간염, E형 간염으로 분류되며, 각각 다른 바이러스가 원인이 됩니다. A형 간염은 급성의 단기적인 질병이나, B형 간염, C형 간염, D형 간염은 대부분 진행성으로 만성적 질병입니다. E형 간염은 일반적으로 급성이나, 임산부에게는 특히 위험한 경우가 있습니다. 간염은 병력 및 신체검사, 간기능 검사, 혈액검사, 초음파 검사 등에서 진단할 수 있습니다. B형 및 C형 간염의 합병증으로는 만성간질환, 간경변, 간암 등이 있습니다.

세계보건기구(WHO)에 따르면 세계에서는 B형 또는 C형 간염에 감염된 사람이 5억 명으로 추정되며, 연간 약 150만 명이 간염 감염으로 사망하고 있고 3명당 1명이 감염되고 있으며, 감염자의 대부분은 휴면 증상으로 인해 이를 알지 못한다고 합니다. 또한 유럽에서는 B형 간염과 C형 간염이 수백만 명에게 영향을 미치고 있습니다. 유럽 질병예방통제센터(ECDC)에 따르면 유럽연합(EU) 회원국에서는 B형 간염의 전체적인 발생률이 1.49(10만 명당), C형 간염은 8.7(10만 명당)로 추정되고 있습니다. 약물을 주사하는 사람의 유병률이 높다고 추정하고 있습니다.

바이러스성 간염의 유병률 증가, 간염 치료제의 유망 파이프라인, 간염 치료제의 채택을 환자에게 촉구하는 정부의 후원적 구상이 간염 치료 시장의 주요 촉진요인입니다.

간염 치료제 시장을 조사했으며, 시장 개요, 시장 성장요인 및 저해요인의 분석, 질환 유형별·약물 유형별·지역별 시장 규모의 추이와 예측, 경쟁 구도, 주요 기업의 개요, 시장 기회 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 시장 성장요인
    • 바이러스성 간염의 유병률 증가
    • 간염에 관한 인식을 생성하기 위한 유리한 정부의 지원
    • 기술적으로 진보한 치료 제품의 가용성 향상
  • 시장 억제요인
    • 엄격한 규제 문제
    • 불충분한 상환 방침
  • Porter's Five Forces 분석

제5장 시장 세분화

  • 질환 유형별
    • A형 간염
    • B형 간염
    • C형 간염
    • D형 간염
    • 기타 유형
  • 약물 클래스별
    • 인터페론
    • 모노클로널 항체
    • 비구조 단백질 5 A(NS5A) 저해제
    • 뉴클레오티드 아날로그 역전사효소 저해제
    • 뉴클레오티드 아날로그 NS5B 폴리메라아제 저해제
    • 멀티 클래스 조합
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동·아프리카
    • 남미

제6장 경쟁 구도

  • 기업 개요
    • Merck & Co., Inc
    • Gilead Sciences, Inc
    • AbbVie Inc
    • Bristol Myers Squibb Company
    • F. Hoffmann-La Roche, Ltd
    • LAURUS Labs
    • Zydus Cadila
    • Hetero Healthcare Limited
    • NATCO Pharma Limited
    • Cipla, Inc

제7장 시장 기회 및 향후 전망

KSA 20.06.18

The hepatitis therapeutics market is projected to register a CAGR of 3.5% during the forecast period.

COVID-19's impact on healthcare resources has adversely affected the delivery of care and outcomes of patients with chronic disease. Therefore, there has been a decrease in the treatment, diagnosis, and follow-up of patients with liver disease and hepatitis, which had negative consequences in the overall healthcare industry. Also, the clinical trials of drugs have been slow down as most of the companies have delayed the start for most of the new studies in several countries. In addition, the COVID-19 pandemic has observed a decrease in outpatient services by patients with chronic hepatitis which further highly impacted the overall market growth.

The market will show rapid growth due to the increasing prevalence of viral hepatitis, favorable government support for creating awareness about hepatitis, and increasing availability of technologically advanced therapeutic products.

Hepatitis is an inflammation, or swelling, of the liver. Hepatitis may occur due to drugs, alcohol use, or certain medical conditions. But in most of the cases, it is caused by a virus called viral hepatitis, and the most common forms are hepatitis A, B, and C. Hepatitis is a very common disease and can lead to serious scarring (cirrhosis) of the liver, which can be fatal.

Some of the common symptoms of hepatitis are loss of appetite, nausea and vomiting, fatigue, fever, body aches, and stomach pain. Some people may experience light-colored bowel movements, dark urine, and yellowing of the skin or of the eyes (jaundice). Viral infections of the liver are classified as hepatitis A, B, C, D, and E. A different virus is responsible for each type of virally transmitted hepatitis. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are mostly ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women. Hepatitis can be diagnosed through history and physical exam, liver function tests, blood tests, and ultrasound. Some of the complications of hepatitis B or C are chronic liver disease, cirrhosis, and liver cancer.

According to the World Health Organization (WHO) 2020, globally, 325 million people are estimated to be infected with hepatitis B or C. In addition, According to WHO, in 2019, Hepatitis B prevalence is highest in the WHO Western Pacific region and the WHO African region, where 6.2% and 6.1% of the adult population is infected respectively.

Moreover, in Europe Hepatitis B and C affect millions of people. According to the World health Organization 2019, Hepatitis B is an infectious disease which has affected around 15 million population in WHO European Region. In addition to the same source Hepatitis C which is a liver disease had affected around 14 million in the European region.

Furthermore, according to the U.S. Department of Health & Human Services, in 2018, most adults in their 20s and 30s made up 36.5% of newly reported chronic hepatitis C infections in the United States and this is expected to increase in the forecast period.

An increase in the prevalence of viral hepatitis, promising pipeline of hepatitis drugs, and supportive government initiatives encouraging patients in the adoption of hepatitis drugs are the key driving factors in the hepatitis therapeutics market.

Key Market Trends

Hepatitis C Segment is Expected to Hold a Major Market Share in the Hepatitis Therapeutics Market

Since the COVID-19 outbreak, the market has been negatively impacted due to the supply chain and market disruption, and by its financial impact on firms and financial markets. The pandemic has negatively impacted the pharmaceutical industry in terms of the supply and demand for different drugs. Similarly, it is also expected to impact the overall growth of the global hepatitis market.

Hepatitis C is a liver infection which is caused by the hepatitis C virus. Hepatitis C can range from a mild to serious and lifelong illness. Acute hepatitis C occurs within the first 6 months after individual is exposed to the hepatitis C virus and chronic hepatitis C can be a lifelong infection with the hepatitis C virus if left untreated.

According to World Health Organization (WHO) 2020, hepatitis C virus (HCV) infection affects over 71 million people globally. According to the same source, the hepatitis C virus is a bloodborne virus and the common mode of infection is through exposure to small quantities of blood. This usually happens with unsafe injection practices and unsafe health care.

Hepatitis C segment holds a significant market share in the hepatitis therapeutics market and is anticipated to show a similar trend over the forecast period due to the high prevalence of hepatitis C in developing and developed regions and the growing availability of effective drug regimens in the market.

Moreover, several product launches by the major players are also boosting the segment growth. For example in 2019 the U.S. Food and Drug Administration approved Mavyret (glecaprevir and pibrentasvir) tablets for the treatment of six genotypes of hepatitis C virus (HCV) in children ages 12 to 17. In additon in 2018 the company Natco Pharma had launched fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C in India

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

The COVID-19 pandemic highlighted the need for North American companies and research organizations to collaborate with the government to develop new drugs, in order to meet future health crisis. In addition, the United States is the most COVID-affected country across the world. The supply chain of products was highly impacted in this country. Initially, the decline in diagnostic and therapeutic procedures has affected the market growth. However, as the restrictions ease, the demand for hepatitis therapeutic will significantly rise and thus drives the overall market growth in the forecasted period.

North America expected to hold a major market share in the hepatitis therapeutics market due to an increase in the incidence of hepatitis, mortality due to hepatitis, and increased spending on drugs for the treatment of hepatitis in this region. According to the Center for Disease Control (CDC) 2018, estimates about 2.4 million people are living with hepatitis C in the United States, and approximately 850,000 people in this region estimated to be living with hepatitis B. In addition to the same source, 67% of persons infected with hepatitis B virus do not know they have the virus. Furthermore, favorable reimbursement policies, high adoption rates of advance therapeutics and the presence of well-established healthcare infrastructure are also fueling the growth of the overall regional market to a large extent.

Furthermore, presence of the key market players coupled with growing awareness programs, recent products launch in the region are anticipated to boost the growth of the market in the United States. For instance, in December 2019, a new strategic plan was initiated in the United States by the National Institutes of Health outlines to intensify ongoing HBV research with the goals of developing a cure and improving scientific understanding of the virus while creating improved strategies for screening and treating patients.

Competitive Landscape

The Hepatitis Therapeutics Market is fragmented competitive and consists of several major players. However, in terms of market share, few of the major players are currently dominating the market. Some of the leading market players include Merck & Co., Inc, Gilead Sciences, Inc, AbbVie Inc, Bristol Myers Squibb Company, F. Hoffmann-La Roche, Ltd, LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, NATCO Pharma Limited and Cipla, Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Viral Hepatitis
    • 4.2.2 Favorable Government Support for Creating Awareness about Hepatitis
    • 4.2.3 Increasing Availability of Technologically Advanced Therapeutic Products
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Issues
    • 4.3.2 Poor Reimbursement Policies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Disease Type
    • 5.1.1 Hepatitis A
    • 5.1.2 Hepatitis B
    • 5.1.3 Hepatitis C
    • 5.1.4 Hepatitis D
    • 5.1.5 Other Types
  • 5.2 By Drug Class
    • 5.2.1 Interferon
    • 5.2.2 Monoclonal Antibody
    • 5.2.3 Non-structural protein 5A (NS5A) inhibitors
    • 5.2.4 Nucleotide Analog Reverse Transcriptase Inhibitors
    • 5.2.5 Nucleotide Analog NS5B Polymerase Inhibitors
    • 5.2.6 Multi Class Combination
    • 5.2.7 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Merck & Co., Inc
    • 6.1.2 Gilead Sciences, Inc
    • 6.1.3 AbbVie Inc
    • 6.1.4 Bristol Myers Squibb Company
    • 6.1.5 F. Hoffmann-La Roche, Ltd
    • 6.1.6 LAURUS Labs
    • 6.1.7 Zydus Cadila
    • 6.1.8 Hetero Healthcare Limited
    • 6.1.9 NATCO Pharma Limited
    • 6.1.10 Cipla, Inc
    • 6.1.11 Johnson & Johnson
    • 6.1.12 Biocon

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q